Payment overview · 2025
General Payments
$607.42
31 reported records · 18 companies
Healthcare provider profile · identity verified
Timothy Benjamin Skelton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BILOXI, MS · NPI 1598867350
Verified facts
What the public records show
CMS Open Payments records show Timothy Benjamin Skelton, MD received $607.42 in general payments during 2025 across 31 reported records.
GlaxoSmithKline, LLC. accounted for 11.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.90 | 11.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.68 | 11.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.32 | 9.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.63 | 8.8% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $42.11 | 6.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.22 | 6.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $35.38 | 5.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.00 | 4.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $25.17 | 4.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $25.15 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.90 | 3.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.38 | 3.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.87 | 3.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.02 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.75 | 3.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.49 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.37 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.08 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $607.42 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $68.68 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.63 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.63 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $52.32 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.26 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| TAKHZYRO Normalized: takhzyro |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $35.38 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| BOOSTRIX Normalized: boostrix |
Biological | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 396 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 86 |
| Lisinopril | Lisinopril | 225 | 68 |
| Omeprazole | Omeprazole | 223 | 76 |
| Losartan Potassium | Losartan Potassium | 178 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 57 |
| Furosemide | Furosemide | 155 | 59 |
| Gabapentin | Gabapentin | 155 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 36 |
| Jardiance | Empagliflozin | 105 | 29 |
| Metformin Hcl | Metformin Hcl | 105 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 32 |
| Simvastatin | Simvastatin | 101 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 37 |
| Carvedilol | Carvedilol | 95 | 30 |
| Trazodone Hcl | Trazodone Hcl | 89 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 29 |
| Ozempic | Semaglutide | 88 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 25 |
| Celecoxib | Celecoxib | 72 | 27 |
| Atenolol | Atenolol | 69 | 21 |
| Potassium Chloride | Potassium Chloride | 68 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 19 |
| Allopurinol | Allopurinol | 64 | 20 |
| Sertraline Hcl | Sertraline Hcl | 64 | 19 |
| Alendronate Sodium | Alendronate Sodium | 62 | 19 |
| Meloxicam | Meloxicam | 62 | 25 |
| Tramadol Hcl | Tramadol Hcl | 62 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 21 |
| Montelukast Sodium | Montelukast Sodium | 60 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 17 |
| Mirtazapine | Mirtazapine | 53 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 17 |
| Glimepiride | Glimepiride | 51 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 12 |
| Ezetimibe | Ezetimibe | 44 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Eliquis | Apixaban | 34 | 11 |
| Famotidine | Famotidine | 34 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 17 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Estradiol | Estradiol | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 12 | 12 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $607.42 · 31 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, BOOSTRIX, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEFFY, OTEZLA, PREVNAR 20, REPATHA, SHINGRIX, TAKHZYRO, TRELEGY ELLIPTA, VRAYLAR, Xolair, YUPELRI, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error